Mifepristone approval delayed, supporters look to action by FDA.
D000019:Abortifacient Agents; D000028:Abortion, Induced; D000569:Americas; D001695:Biology; D003257:Consumer Product Safety; D019049:Developed Countries; D004703:Endocrine System; D005193:Family Planning Services; D006077:Government Agencies; D006727:Hormone Antagonists; D006728:Hormones; D007878:Legislation as Topic; D015735:Mifepristone; D009656:North America; D009938:Organizations; D010827:Physiology; D014481:United States; D014486:United States Food and Drug Administration; D014492:United States Public Health Service
D000019:Abortifacient Agents; D006727:Hormone Antagonists; D006728:Hormones; D015735:Mifepristone
Abortifacient Agents; Abortion, Drug Induced; Abortion, Induced; Americas; Biology; Developed Countries; Endocrine System; Family Planning; Fertility Control, Postconception; Government Agencies; Hormone Antagonists; Hormones; Legislation; North America; Northern America; Organizations; Physiology; Product Approval; Ru-486; United States; Usfda; Usphs